Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CCR8 | P51685 | 4/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15243730 | 0.88 | MBTD1 (0.62) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL6499571 | 0.83 | ALDH1A1 (0.75) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL13943667 | 0.83 | SIGMAR1 (0.64) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| SCHEMBL27745212 | 0.82 | ACHE (0.60) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| SCHEMBL6496864 | 0.82 | ALDH1A1 (0.73) | ALDH1A1KDM4ETDP1HPGDHTT | |
| SCHEMBL2336883 | 0.81 | KDM4E (0.65) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| SCHEMBL16226310 | 0.81 | KDM4E (0.54) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| SCHEMBL15509393 | 0.81 | MBTD1 (0.52) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL2331568 | 0.80 | KDM4E (0.63) | ALDH1A1KDM4ETRPV6SMN1; SMN2SIGMAR1 | |
| SCHEMBL6501384 | 0.80 | ALDH1A1 (0.66) | ALDH1A1KDM4ETDP1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | THE CLEVELAND CLINIC FOUNDATION | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257350-A1 | COMPOUNDS AND METHODS OF PROMOTING OLIGODENDROCYTE PRECURSOR DIFFERENTIATION | CHAT, DCX, GAP43 | ALDH1A1 611/4885KDM4E 3073/4885TDP1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.